Source: NICE
Area: Evidence > Drug Specific Reviews
NICE has issued final guidance that does not support the use of fluocinolone acetonide intravitreal implant (Iluvien) for the treatment of chronic diabetic macular oedema considered insufficiently responsive to available therapies (TA 271).
The Committee noted that fluocinolone acetonide intravitreal implants do not provide enough benefit to patients to justify their high cost.
See links below for further details.
Uncategorized